Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

      Interim Management Statement - 3 months to 30 June 2011 (unaudited)      

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, 
biotechnology and related companies in the healthcare sector with the objective
of achieving a high level of capital growth.

The three month period ended 30 June 2011 was a positive one for the Company
due in part to strong performance from large capitalisation pharmaceutical
stocks and the Company's Japanese generic drug pharmaceutical holdings,
together with the release of positive new product data. Over the three-month
period, the Company's net asset value total return was +9.9% and the share
price total return was +12.0%, compared to a rise of 8.1% in the Company's
benchmark, the MSCI World Health Care Index measured on a total return basis in
sterling terms. In the period from 30 June 2011 to 1 August 2011, Company's net
asset value total return was -4.1% and the share price total return was +1.3%,
compared to a fall of 4.4% in the Company's benchmark.

During the three month period and to the date of this report no shares were
repurchased by the Company. On 28 July 2011 the Company cancelled all of the
358,607 shares held in treasury.

Also, on 2 August 2011, a total of 354,240 new shares were issued, raising £
2.3m of additional funds for the Company, as a result of holders of
subscription shares exercising their subscription rights.

At the Company's Annual General Meeting, held on 7 July 2011, all of the
resolutions were passed.

The Company paid an increased interim dividend of 15.0p per share (2010: 8.5p
per share) on 30 June 2011.

Trust Characteristics

                            30 June 2011             31 March 2011             
                                                                               
Number of holdings          69                       60                        
                                                                               
Net assets (£m)             367.9                    337.7                     
                                                                               
Net yield                   2.0%                     1.2%                      
                                                                               
Gearing (AIC basis)         116                      114                       
                                                                               
Share price (p)             753.00                   686.00                    
                                                                               
NAV (p) -undiluted          852.52                   782.82                    
                                                                               
NAV (p) diluted: sub shares 818.36                   759.71                    
                                                                               
NAV (p) - fully diluted for 817.90                   759.20                    
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
Discount (undiluted)        (11.7%)                  (12.4%)                   
                                                                               
Discount (diluted - sub     (8.0%)                   (9.7%)                    
shares)                                                                        
                                                                               
Discount (fully diluted)    (7.9%)                   (9.6%)                    
                                                                               
Subscription share price    109.00                   84.50                     
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                                at 30 June 2011           at 31 March 2011     
                                                                               
Pfizer                                5.3                       6.2            
                                                                               
Novartis                              5.2                       4.6            
                                                                               
Roche                                 4.9                       6.0            
                                                                               
Johnson & Johnson                     4.1                       4.0            
                                                                               
Bristol-Myers Squibb                  3.8                       3.8            
                                                                               
Mitsubishi Tanabe Pharma              3.8                       4.0            
                                                                               
Merck & Co.                           3.4                       3.5            
                                                                               
Wellpoint                             2.7                       2.7            
                                                                               
Allergen                              2.7                       2.6            
                                                                               
Gilead Sciences                       2.6                       1.7            
                                                                               
                                     38.5                       39.1           

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                                at 30 June 2011           at 31 March 2011     
                                                                               
Large capitalisation                 64.9                       67.2           
                                                                               
Small capitalisation                 35.1                       32.8           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                               at 30 June 2011            at 31 March 2011     
                                                                               
North America                        67.2                       63.5           
                                                                               
Europe                               19.6                       21.6           
                                                                               
Far East                             12.6                       13.8           
                                                                               
Israel                               0.6                        1.1            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +12.0%          +20.2%          +76.2%          +64.5%         
                                                                               
NAV Fully       +9.9%           +20.7%          +75.1%          +74.4%         
diluted                                                                        
                                                                               
Benchmark*      +8.1%           +21.2%          +58.3%          +51.6%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Bloomberg and Thomson Reuters

* With effect from 1 October 2010, the performance of the Company is measured
against the MSCI World Health Care Index measured on a total return basis in
sterling terms. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index on a total return basis
in sterling terms. Historic data, therefore, consists of a blended figure
containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Subscription Shares - B3VMCB0

ISIN -

Shares - GB0003385308

Subscription Shares - GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

3 August 2011